# Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases

> **NCT07660783** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Bone Marrow Failure
- Hemoglobinopathies
- Primary Immune Deficiency (PID)
- Autoimmune Cytopenia
- Immune Dysregulation
- Hemophagocytic Lymphohistiocytosis (HLH)
- Non Malignant Disorders

## Interventions

- **BIOLOGICAL:** ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs

## Key facts

- **NCT ID:** NCT07660783
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2031-09
- **Final completion:** 2035-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07660783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07660783, "Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07660783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*